However, our study does highlight the unique genomic makeup of MTAP deficient NSCLC and provides a basis from which, further studies assessing therapeutic agents that exploit synthetic lethality‐based approaches in this disease can be designed. The gene discussed is MTAP; the disease is non-small cell lung carcinoma.